ABT vs DVA: fair value comparison
Abbott Laboratories and DaVita Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DVA currently sits closer to the top of our discount ranking. ABT carries the stronger quality grade.
| ABT | DVA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $112.47 | $180.68 |
| 12-month range | $87.78–$131.46 | $111.19–$240.09 |
| Sector rank | #43 of 113 Healthcare | #39 of 113 Healthcare |
| Quality grade | B | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Oversold |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · DVA fair value analysis